|
|
1105 Maywood Drive
Belmont, CA 94002 USA
phone:650.587.6271
fax:
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
3 |
|
|
| www.genesismedical.net
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Funnel Catheter Treatment for Occlusive Vascular Diseases |
|
| Management |
| William (Will) R. Dubrul, Founder, Director, President & CEO; Andrei M. Manoliu, Ph.D., J.D., Founder & Director; Anne Worden, VP of Regulatory Affairs and Quality Assurance; Brent Seybold, Director of Product Development; Jennifer Strezo, Business Operations Manager |
| |
|
|
| |
|
| Keywords |
| funnel, catheter, funnel catheter, cardiology, emboli, clot, occlusion |
|
|
|
| Description |
|
Genesis Technologies, LLC. is a medical device company committed to advancing cardiovascular healthcare by designing safe, easy-to-use products to treat occlusive vascular diseases. The company believes its products will improve patient care and quality of life when used during percutaneous interventional procedures. |
|
| Products / Services |
The Genesis F.A.S.T. Funnel Catheter is a line of innovative medical devices comprised of a funnel deployed at the distal end of the catheter to stop blood flow for temporary occlusion. Once the patient's blood flow has stopped, dangerous emboli and thrombi can be easily aspirated through the funnel catheter. Genesis has also begun development of DESA (Drug-Eluting Scoring Angioplasty), a technology with the potential to replace cardiovascular stents. With a stent-like structure wrapped around an angioplasty balloon, microfractures occur in the stenosis and drugs can be delivered simultaneously.
|
|
| Technology / Differentiation |
| The F.A.S.T. Funnel Catheter employs a novel design that harnesses native blood pressure to provide the sealing force for occlusion. Other occluders on the market utilize balloons that exert higher forces against the wall of the blood vessel and take longer to inflate and deflate, as compared to the Genesis 'Instant On/Instant Off' mechanism of action. As the funnel occluder is deployed in the vasculature, the distal end forms a cone shape to help facilitate complete aspiration of emboli and thrombi. The Genesis DESA utilizes an old and inexpensive technology (tubular mesh braids), allowing the company to keep standard costs below that of competitive cutting balloons. |
|
| Market / Customers |
Genesis has licensed the Funnel Catheter technology to MICRUS Endovascular to treat acute stroke in the brain, a formidable market selling to interventional neuroradiologists (INR's). Another even larger market is embolic protection during Acute Myocardial Infarction intervention (stenting); the cardiologist is the customer base in this case. The DESA will be marketed to all vascular interventionalists (cardiologists, interventional radiologists & nephrologists, vascular surgeons). These markets are collectively valued at over $5 billion.
|
|
| Status |
| Trials at TCT 2008 demonstrated that proximal embolic protection saved heart tissue during heart attack intervention; previous randomized trials with distal embolic protection showed the opposite. The company's technologies are protected by several patents. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members